| Welcome to the Philadelphia Cancer Treatment website. This website will guide you to the next step in treating your prostate or bladder cancer. After navigating this website, you will know the basics of prostate and bladder cancer, become acquainted with the procedures and therapies most commonly used in treatment, be familiar with our latest technologies, and have a clearer view of our ClubCare™ approach to patient care. ClubCare™ is personalized cancer care that employs advanced technology and academic research excellence in a uniquely comfortable and supportive environment. |
Latest Cancer News
Active Surveillance Linked with Better Quality of Life in Prostate Cancer
(12-16-2010)
It appears that men diagnosed with low-risk prostate cancer who choose active surveillance instead of initial treatment may enjoy a better quality of life. These findings were recently reported in the... Continue Reading
Xgeva Delays Spread of Prostate Cancer to Bone (12-15-2010)
Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. Full results from this study are expected to... Continue Reading
Committee Votes Against Use of Drugs for Prostate Cancer Risk Reduction (12-9-2010)
An advisory committee to the US Food and Drug Administration (FDA) has voted against expanding the approval of Avodart® (dutasteride) and Proscar® (finasteride) to include prostate cancer risk reduction. For... Continue Reading
It appears that men diagnosed with low-risk prostate cancer who choose active surveillance instead of initial treatment may enjoy a better quality of life. These findings were recently reported in the... Continue Reading
Xgeva Delays Spread of Prostate Cancer to Bone (12-15-2010)
Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. Full results from this study are expected to... Continue Reading
Committee Votes Against Use of Drugs for Prostate Cancer Risk Reduction (12-9-2010)
An advisory committee to the US Food and Drug Administration (FDA) has voted against expanding the approval of Avodart® (dutasteride) and Proscar® (finasteride) to include prostate cancer risk reduction. For... Continue Reading
More Cancer News
Locations
Radiation Oncology CenterOne Presidential Blvd.
Suite 100
Bala Cynwyd, PA 19004
phone: 610-632-4100
fax: 610-668-1067
_________________________________________
RapidArc
RapidArc™ is a technology that improves the consistency of the radiation dose while making treatment up to eight times faster. It allows the beam to irradiate the entire tumor rather than irradiating it in segments as with older technologies.